{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:14:54Z","timestamp":1786986894213,"version":"build-2736575974"},"reference-count":56,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.clml.2017.06.007","type":"journal-article","created":{"date-parts":[[2017,6,19]],"date-time":"2017-06-19T18:15:14Z","timestamp":1497896114000},"page":"667-675.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Baseline Characteristics Predicting Very Good Outcome of Allogeneic Hematopoietic Cell Transplantation in Young Patients With High Cytogenetic Risk Chronic Lymphocytic Leukemia\u00a0- A Retrospective Analysis From the Chronic Malignancies Working Party of the EBMT"],"prefix":"10.1016","volume":"17","author":[{"given":"Michel","family":"van Gelder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitris","family":"Ziagkos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liesbeth","family":"de Wreede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"van Biezen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Dreger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Gramatzki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Stelljes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels Smedegaard","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolaas","family":"Schaap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonin","family":"Vitek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dietrich","family":"Beelen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vesa","family":"Lindstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Finke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Passweg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Eder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maciej","family":"Machaczka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio","family":"Delgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Kr\u00fcger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lud\u011bk","family":"Raida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard","family":"Soci\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavel","family":"Jindra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1235-4530","authenticated-orcid":false,"given":"Boris","family":"Afanasyev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Chalandon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Henseler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Schoenland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolaus","family":"Kr\u00f6ger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Schetelig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2017.06.007_bib1","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia","volume":"371","author":"Byrd","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2017.06.007_bib2","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa1315226","article-title":"Idelalisib and rituximab in relapsed chronic lymphocytic leukemia","volume":"370","author":"Furman","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2017.06.007_bib3","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2017.06.007_bib4","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1182\/blood.V128.22.233.233","article-title":"Five-year experience with single-agent ibrutinib in patients with previously untreated and relapsed\/refractory chronic lymphocytic leukemia\/small lymphocytic leukemia","volume":"128","author":"O'Brien","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.06.007_bib5","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1182\/blood.V128.22.637.637","article-title":"Venetoclax (VEN) monotherapy for patients with chronic lymphocytic leukemia (CLL) who relapsed after or were refractory to ibrutinib or idelalisib","volume":"128","author":"Jones","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.06.007_bib6","doi-asserted-by":"crossref","first-page":"4400","DOI":"10.1182\/blood.V128.22.4400.4400","article-title":"Optimal sequencing of ibrutinib, idelalisib, and venetoclax in CLL: results from a large multi-center study of 683 US patients","volume":"128","author":"Mato","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.06.007_bib7","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1182\/blood-2014-10-606038","article-title":"Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib","volume":"125","author":"Byrd","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.06.007_bib8","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/S1470-2045(16)30212-1","article-title":"Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study","volume":"17","author":"O'Brien","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2017.06.007_bib9","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1182\/blood.V128.22.55.55","article-title":"The development and expansion of resistant subclones precedes relapse during ibrutinib therapy in patients with CLL","volume":"128","author":"Woyach","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.06.007_bib10","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.3324\/haematol.2016.144576","article-title":"Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program","volume":"101","author":"Winqvist","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2017.06.007_bib11","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1182\/blood.V128.22.3223.3223","article-title":"Clinicopathological features and outcomes of progression for chronic lymphocytic leukaemia (CLL) treated with the BCL2 inhibitor venetoclax","volume":"128","author":"Lew","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.06.007_bib12","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.1182\/blood.V126.23.2945.2945","article-title":"Outcomes of patients with relapsed\/refractory chronic lymphocytic leukemia after ibrutinib discontinuation outside clinical trials: a single institution experience","volume":"126","author":"Sandoval-Sus","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.06.007_bib13","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1182\/blood-2016-05-716977","article-title":"Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience","volume":"128","author":"Mato","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.06.007_bib14","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1182\/blood-2014-09-603670","article-title":"Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib","volume":"125","author":"Jain","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.06.007_bib15","doi-asserted-by":"crossref","first-page":"4912","DOI":"10.1200\/JCO.2007.15.4757","article-title":"Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning","volume":"26","author":"Sorror","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.06.007_bib16","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/leu.2012.228","article-title":"Long-term follow-up of reduced-intensity allogeneic stem cell transplantation for chronic lymphocytic leukemia: prognostic model to predict outcome","volume":"27","author":"Brown","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2017.06.007_bib17","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1182\/blood-2010-03-275420","article-title":"Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial","volume":"116","author":"Dreger","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.06.007_bib18","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1038\/bmt.2015.150","article-title":"Allogeneic hematopoietic stem cell transplantation for poor-risk CLL: dissecting immune-modulating strategies for disease eradication and treatment of relapse","volume":"50","author":"Hahn","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2017.06.007_bib19","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1038\/leu.2010.165","article-title":"The impact of HLA matching on long-term transplant outcome after allogeneic hematopoietic stem cell transplantation for CLL: a retrospective study from the EBMT registry","volume":"24","author":"Michallet","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2017.06.007_bib20","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1182\/blood-2012-11-469627","article-title":"TP53, SF3B1, and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trial","volume":"121","author":"Dreger","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.06.007_bib21","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/bmt.2016.282","article-title":"Long-term survival of patients with CLL after allogeneic transplantation: a report from the European Society for Blood and Marrow Transplantation","volume":"52","author":"van Gelder","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2017.06.007_bib22","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/j.leukres.2014.04.006","article-title":"Genomic aberrations deletion 11q and deletion 17p independently predict for worse progression-free and overall survival after allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia","volume":"38","author":"Chavez","year":"2014","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2017.06.007_bib23","doi-asserted-by":"crossref","first-page":"4715","DOI":"10.1002\/cncr.24531","article-title":"Risk score for outcome after allogeneic hematopoietic stem cell transplantation: a retrospective analysis","volume":"115","author":"Gratwohl","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2017.06.007_bib24","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.cmpb.2010.01.001","article-title":"The mstate package for estimation and prediction in non- and semi-parametric multi-state and competing risks models","volume":"99","author":"de Wreede","year":"2010","journal-title":"Comput Methods Programs Biomed"},{"key":"10.1016\/j.clml.2017.06.007_bib25","series-title":"Flexible imputation of missing data","author":"van Buuren","year":"2012"},{"key":"10.1016\/j.clml.2017.06.007_bib26","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1182\/blood-2010-09-308775","article-title":"Autologous hematopoietic stem cell transplantation in chronic lymphocytic leukemia: results of European intergroup randomized trial comparing autografting versus observation","volume":"117","author":"Michallet","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.06.007_bib27","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/bmt.2016.329","article-title":"Risk factors for treatment failure after allogeneic transplantation of patients with CLL: a report from the European Society for Blood and Marrow Transplantation (EBMT)","volume":"52","author":"Schetelig","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2017.06.007_bib28","doi-asserted-by":"crossref","first-page":"4576","DOI":"10.1182\/blood-2007-06-097386","article-title":"High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation","volume":"110","author":"Lee","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.06.007_bib29","doi-asserted-by":"crossref","first-page":"3908","DOI":"10.1182\/blood-2011-09-381699","article-title":"Outcomes after matched unrelated donor versus identical sibling hematopoietic cell transplantation in adults with acute myelogenous leukemia","volume":"119","author":"Saber","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.06.007_bib30","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1182\/blood-2013-04-496778","article-title":"Impact of donor source on hematopoietic cell transplantation outcomes for patients with myelodysplastic syndromes (MDS)","volume":"122","author":"Saber","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.06.007_bib31","doi-asserted-by":"crossref","first-page":"3220","DOI":"10.1182\/blood-2013-02-482547","article-title":"High-resolution HLA matching in hematopoietic stem cell transplantation: a retrospective collaborative analysis","volume":"122","author":"Furst","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.06.007_bib32","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1182\/blood-2010-04-278317","article-title":"Comparable survival after HLA-well-matched unrelated or matched sibling donor transplantation for acute myeloid leukemia in first remission with unfavorable cytogenetics at diagnosis","volume":"116","author":"Gupta","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.06.007_bib33","doi-asserted-by":"crossref","first-page":"999","DOI":"10.3109\/10428194.2014.944518","article-title":"Allogeneic hematopoietic stem cell transplant for hematological malignancies from mismatched 9\/10 human leukocyte antigen unrelated donors: comparison with transplants from 10\/10 unrelated donors and human leukocyte antigen identical siblings","volume":"56","author":"Michallet","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2017.06.007_bib34","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1016\/j.bbmt.2010.03.024","article-title":"HLA-allele matched unrelated donors compared to HLA-matched sibling donors: role of cell source and disease risk category","volume":"16","author":"Woolfrey","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2017.06.007_bib35","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/bmt.2014.4","article-title":"Matched unrelated donor allogeneic transplantation provides comparable long-term outcome to HLA-identical sibling transplantation in relapsed diffuse large B-cell lymphoma","volume":"49","author":"Avivi","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2017.06.007_bib36","doi-asserted-by":"crossref","first-page":"6109","DOI":"10.1182\/blood-2010-11-317073","article-title":"Autologous stem cell transplantation as a first-line treatment strategy for chronic lymphocytic leukemia: a multicenter, randomized, controlled trial from the SFGM-TC and GFLLC","volume":"117","author":"Sutton","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.06.007_bib37","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1046\/j.1365-2141.2000.01900.x","volume":"108","author":"Michallet","year":"2000","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2017.06.007_bib38","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1002\/ajh.23610","article-title":"Improved relapse-free survival after autologous stem cell transplantation does not translate into better quality of life in chronic lymphocytic leukemia: lessons from the randomized European Society for Blood and Marrow Transplantation-Intergroup study","volume":"89","author":"de Wreede","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2017.06.007_bib39","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1093\/annonc\/mdt511","article-title":"The impact of allogeneic stem cell transplantation on the natural course of poor-risk chronic lymphocytic leukemia as defined by the EBMT consensus criteria: a retrospective donor versus no donor comparison","volume":"25","author":"Herth","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2017.06.007_bib40","doi-asserted-by":"crossref","first-page":"711","DOI":"10.3109\/10428194.2014.930848","article-title":"Allogeneic stem cell transplant in patients with chronic lymphocytic leukemia with 17p deletion: consult-transplant versus consult- no-transplant analysis","volume":"56","author":"Poon","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2017.06.007_bib41","doi-asserted-by":"crossref","first-page":"4657","DOI":"10.1182\/blood.V128.22.4657.4657","volume":"128","author":"Dreger","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.06.007_bib42","unstructured":"Schetelig J. Bridging with idelalisib is safe in patients with chronic lymphocytic leukemia (CLL) prior to allogeneic hematopoietic stem cell transplantation (alloHCT): a report from the EBMT Chronic Malignancy Working Party, 43rd Annual Meeting of the European Society for Blood and Marrow Transplantation, oral session 18: chronic leukemia and MDS, 5th abstract. Available at: http:\/\/cme-utilities.com\/mailshotcme\/Abstracts\/Physicians%20Oral%2018%20Abstracts%20090317.pdf."},{"key":"10.1016\/j.clml.2017.06.007_bib43","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/bmt.2015.339","article-title":"Durable responses to ibrutinib in patients with relapsed CLL after allogeneic stem cell transplantation","volume":"51","author":"Link","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2017.06.007_bib44","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1111\/bjh.14029","article-title":"Recovery of full donor chimerism with ibrutinib therapy in relapsed CLL after allogeneic stem cell transplantation","volume":"176","author":"Quinquenel","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2017.06.007_bib45","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1200\/JCO.2014.58.6750","article-title":"Outcomes of patients with chronic lymphocytic leukemia and richter's transformation after transplantation failure","volume":"33","author":"Rozovski","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.06.007_bib46","doi-asserted-by":"crossref","first-page":"4697","DOI":"10.1182\/blood.V124.21.4697.4697","article-title":"Safety and efficacy of ibrutinib in patients with relapsed\/refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma who have undergone prior allogeneic stem cell transplant","volume":"124","author":"Coutre","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.06.007_bib47","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.1200\/JCO.2013.53.8157","article-title":"Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation","volume":"32","author":"Sorror","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.06.007_bib48","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1182\/blood-2012-03-414573","article-title":"Validation of the hematopoietic cell transplantation-specific comorbidity index: a prospective, multicenter GITMO study","volume":"120","author":"Raimondi","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.06.007_bib49","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s11899-014-0242-1","article-title":"Where does allogeneic stem cell transplantation fit in the treatment of chronic lymphocytic leukemia?","volume":"10","author":"Dreger","year":"2015","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.clml.2017.06.007_bib50","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1200\/JCO.2016.68.2856","article-title":"Economic burden of chronic lymphocytic leukemia in the era of oral targeted therapies in the United States","volume":"35","author":"Chen","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.06.007_bib51","doi-asserted-by":"crossref","first-page":"5259","DOI":"10.1182\/blood.V112.11.325.325","volume":"112","author":"Hallek","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.06.007_bib52","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","article-title":"Defining the intensity of conditioning regimens: working definitions","volume":"15","author":"Bacigalupo","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2017.06.007_bib53","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.bbmt.2008.04.003","article-title":"Classification of HLA-matching for retrospective analysis of unrelated donor transplantation: revised definitions to predict survival","volume":"14","author":"Weisdorf","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2017.06.007_bib54","series-title":"Flexible imputation of missing data","author":"van Buuren","year":"2012"},{"key":"10.1016\/j.clml.2017.06.007_bib55","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1080\/10705510802339072","article-title":"What improves with increased missing data imputations?","volume":"15","author":"Bodner","year":"2008","journal-title":"Structural Equation Modeling"},{"key":"10.1016\/j.clml.2017.06.007_bib56","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/sim.4067","article-title":"Multiple imputation using chained equations: issues and guidance for practice","volume":"30","author":"White","year":"2011","journal-title":"Stat Med"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226501730191X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226501730191X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,10]],"date-time":"2020-10-10T07:56:09Z","timestamp":1602316569000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S215226501730191X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":56,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["S215226501730191X"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2017.06.007","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Baseline Characteristics Predicting Very Good Outcome of Allogeneic Hematopoietic Cell Transplantation in Young Patients With High Cytogenetic Risk Chronic Lymphocytic Leukemia\u00a0- A Retrospective Analysis From the Chronic Malignancies Working Party of the EBMT","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2017.06.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}